Experimental virus therapy takes on deadly brain tumors
NCT ID NCT07472790
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment for recurrent high-grade glioma, an aggressive brain cancer. The approach uses a specially designed virus injected directly into the tumor to kill cancer cells and boost the immune system, combined with a PD-1 inhibitor drug that helps the immune system attack the cancer. The study will enroll 15 adults whose cancer has returned after standard treatment, to see if the combination is safe and how long they live.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oncolytic virus Ad-TD-nsIL12 combined with a PD-1 inhibitor
What this could lead to
If successful, this could point toward a new treatment option for recurrent high-grade glioma, a brain cancer with few effective therapies.
What could go wrong
This is a very early Phase 1 trial with only 15 people, so it is too soon to know if the combination works or is safe. The virus and immune drug may cause serious side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
Contact Phone: •••-•••-•••• Email: •••••@•••••